• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

This product is currently not available for purchase.

RELATED PRODUCTS

Stakeholder Opinions: Skin and Soft Tissue Infections Product Image

Stakeholder Opinions: Skin and Soft Tissue Infections

  • ID: 1059168
  • July 2009
  • 94 pages
  • Datamonitor

Treatment of skin and skin structure infections often requires systemic antibacterial therapy. Two trends are concerning physicians: the spread of methicillin-resistant Staphylococcus aureus (MRSA), particularly community-acquired strains (CA-MRSA) have become the most important pathogen in the US; and a slow but measurably declining susceptibility to vancomycin by these bacteria.

Scope

- Epidemiological trends and economic impact of key pathogens

- Overview of diagnosis and referral patterns

- Analysis of present and future unmet needs with outline of key drugs in development for SSTIs

- Outline of drivers of treatment choice in both the hospital and the community setting

Highlights of this title

Guideline adoption for skin and soft tissue infections (SSTIs) among specialists is fairly strong, but less so among primary care physicians (PCPs). PCPs treat mild-to-moderate forms of disease, representing an estimated 70% of SSTI patients, while specialists treat severe SSTI sufferers (30%).

Resistance is the single most important factor affecting the SSTI drug market, in both the community and hospital settings. Vancomycin has traditionally READ MORE >



Chapter 1 EXECUTIVE SUMMARY
Scope of the analysis
Insight into the skin and soft tissue infections market
Contributing experts
Related reports
Upcoming related reports

Chapter 2 EPIDEMIOLOGY AND DISEASE BACKGROUND
Etiology and symptoms
Types of skin and soft tissue infections
Cellulitis
Erysipelas
Erythrasma
Folliculitis and skin abscesses
Impetigo
Furunculosis
Lymphadenitis
Lymphangitis
Necrotizing skin infections
Staphylococcal scalded skin syndrome
Complicated and uncomplicated skin and soft tissue infections
Recurrent skin and soft tissue infections
Pathogens
Staphylococcus and Streptococcus bacterial species are the main SSTI pathogens in both the community and hospital settings
Staphylococcus aureus
Methicillin-resistant Staphylococcus aureus (MRSA)
Risk groups
General risk factors for SSTIs
Epidemiological trends
SSTIs are a major driver for ambulatory care utilization
US
Increasing incidence of SSTIs in the US may be driven by CA-MRSA
Incidence of MRSA is lower in Japan compared to the US and Europe
Europe
Economic burden of skin and soft tissue infections

Chapter 3 PRESENTATION, DIAGNOSIS AND REFERRAL OPTIONS
Overview
Presentation
Diagnosis
Diagnosis of skin and soft tissue infections is commonly based purely on clinical impression
Guidelines for the diagnosis and management of skin and soft tissues infections are sparse across the seven major markets
Laboratory tests used in the diagnosis of skin and soft tissue infections
Tissue swab with bacterial culture
Blood cultures
Needle aspiration
X-rays and ultrasound
Computed tomography (CT) and magnetic resonance imaging (MRI) scans
Gram stain
Referral
Primary care physicians treat most skin and soft tissue infections, although a referral may be made in more severe cases
Reasons for hospital admission for SSTIs
Mild-to-moderate nosocomial skin and soft tissue infections are treated by the attending physician
Unmet needs and future developments in the diagnosis of skin and soft tissue infections
Cepheid has developed a rapid molecular diagnostic test for SSTIs caused by MRSA and methicillin-susceptible S. aureus

Chapter 4 CURRENT TREATMENT OPTIONS AND TRENDS
Market overview
Treatment guidelines
Guideline adherence for SSTIs is strong among specialists, but poor among primary care physicians
Treatment options
Current skin and soft tissue infection therapies
Levofloxacin
Ciprofloxacin
Moxifloxacin
Imipenem and cilastatin
Clindamycin
Daptomycin
Linezolid
Tigecycline
Cefazolin
Cefalexin
Vancomycin
Piperacillin/tazobactam
Quinupristin/dalfopristin
Resistance issues for skin and soft tissue infections
Resistance issues are growing for bacterial skin and soft tissue infections caused by staphylococci and streptococci
Studies and key opinion leaders acknowledge that vancomycin is becoming less effective at treating SSTIs caused by MRSA
Emerging pathogens
Community-acquired methicillin-resistant Staphylococcus aureus is the most dangerous emerging pathogen for skin and soft tissue infections
Treatment choice
Efficacy against pathogens is highly influential in treatment choice for skin and soft tissue infections, although safety and cost also play a role

Chapter 5 UNMET NEEDS AND NEW DEVELOPMENTS
Unmet needs and future developments
Gaining regulatory approval represents a significant challenge for pharmaceutical companies developing drugs for the treatment of skin and soft tissue infections
The different characteristics of therapies can all contribute to the uptake of new antibacterial drugs for SSTIs
Treatment satisfaction
Variation in resistance patterns may be highly influential in the levels of skin and soft tissue infection treatment satisfaction expressed by physicians
Unmet needs in the treatment of skin and soft tissue infections
Despite the availability of efficacious therapies and a busy pipeline, increasing resistance highlights the need for novel skin and soft tissue infection drugs
Key pipeline drugs in development for skin and soft tissue infections
Telavancin
Ceftobiprole
Oritavancin
Ceftaroline
Iclaprim
Torezolid
Dalbavancin
Radezolid (RX-1741)
Delafloxacin (RX-331)
Razupenem (PZ-601)

BIBLIOGRAPHY
Journal papers
Websites

APPENDIX A
Contributing experts

APPENDIX B
Disclaimer

List of Tables
Table 1: Occurrence of pathogens causing skin and soft tissue infections in North America, Europe, Latin America, and Asia-Pacific region, 1999-2004
Table 2: Occurrence of pathogens responsible for causing skin and soft tissue infections in the US and Canada, 1997-2000
Table 3: Etiologic risk factors for skin and soft tissue infections and their associated bacterial causes
Table 4: Drug susceptibilities of methicillin-susceptible Staphylococcus aureus isolated from SSTI outpatients across the US, France, Germany, Italy, and Spain, 2001
Table 5: Drug susceptibilities of methicillin-resistant Staphylococcus aureus isolated from SSTI outpatients across the US, France, Germany, Italy, and Spain, 2001
Table 6: Drug susceptibilities of methicillin-susceptible Staphylococcus aureus isolated from SSTI inpatients and intensive care unit patients across the US, France, Germany, Italy, and Spain, 2001
Table 7: Drug susceptibilities of methicillin-resistant Staphylococcus aureus isolated from SSTI inpatients and intensive care unit patients across the US, France, Germany, Italy, and Spain, 2001
Table 8: Drug susceptibilities of Streptococcus pyogenes isolated from SSTI inpatients and intensive care unit patients across the US, France, Germany, Italy, and Spain, 2001
Table 9: Vancomycin susceptibility results for Staphylococcus aureus isolates across the five major EU markets, 2001-06
Table 10: Importance of different characteristics of drugs in treatment choice in both the community and hospital settings

Note: Product cover images may vary from those shown

Our Clients

Our clients' logos